亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

榮大醫藥化工有限公司  

阿那曲唑,拉帕替尼,伊班膦酸鈉,氟維司群,恩替卡韋,鹽酸帕洛諾司瓊,索拉菲尼,鹽酸美金剛胺,鹽酸米那普倫,利托那韋中間體,胡椒酸,伊馬替尼,來曲唑,磷酸奧司他韋等

搜索
網站公告
阿那曲唑,拉帕替尼,伊班膦酸鈉,氟維司群,恩替卡韋,鹽酸帕洛諾司瓊,索拉菲尼,鹽酸美金剛胺,鹽酸米那普倫,利托那韋中間體,胡椒酸,伊馬替尼,來曲唑,磷酸奧司他韋等
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:黎女士
  • 電話:0571-28182190
  • 郵件:shelly@rdpharm.com
  • 傳真:0571-28281887
  • QQ:1833436340
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 1,2,3,4-四氫-1-萘甲酸 85977-52-2
1,2,3,4-四氫-1-萘甲酸 85977-52-2
單價 面議對比
詢價 暫無
發貨 浙江湖州市付款后3天內
品牌 榮大
型號 85977-52-2
規格 99%
過期 長期有效
更新 2014-03-25 13:24
 
詳細信息
 

(S)-(-)-1,2,3,4-四氫-1-萘甲酸

基本信息
英文名   (S)-(-)-1,2,3,4-Tetrahedro-naphthoic acid
產品名稱   (S)-(-)-1,2,3,4-四氫-1-萘甲酸
copyRight
分子結構   CAS 登錄號:85977-52-2, (S)-(-)-1,2,3,4-四氫-1-萘甲酸
 
分子式   C11H12O2
分子量   176.21
CAS 登錄號   85977-52-2
©2025 榮大醫藥化工有限公司 版權所有   技術支持:化工網   訪問量:7275  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |